{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,23]],"date-time":"2026-09-23T23:28:59Z","timestamp":1790206139496,"version":"4.1.0"},"reference-count":37,"publisher":"Oxford University Press (OUP)","issue":"5","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2005,5,1]]},"DOI":"10.1093\/jac\/dki062","type":"journal-article","created":{"date-parts":[[2005,3,11]],"date-time":"2005-03-11T02:54:54Z","timestamp":1110509694000},"page":"612-615","source":"Crossref","is-referenced-by-count":24,"title":["Therapeutic approaches to combating lipoatrophy: do they work?"],"prefix":"10.1093","volume":"55","author":[{"given":"Allison","family":"Martin","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Patrick W. G.","family":"Mallon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2005,5]]},"reference":[{"key":"key\n\t\t\t\t20171012173625_R1","doi-asserted-by":"crossref","unstructured":"Miller, J., Carr, A., Emery, S. et al. (2003). HIV lipodystrophy: prevalence, severity and correlates of risk in Australia. HIV Medicine4, 293\u2013301.","DOI":"10.1046\/j.1468-1293.2003.00159.x"},{"key":"key\n\t\t\t\t20171012173625_R2","unstructured":"Timar, O., Sestier, F. & Levy, E. (2000). Metabolic syndrome X: a review. Canadian Journal of Cardiology16, 779\u201389."},{"key":"key\n\t\t\t\t20171012173625_R3","doi-asserted-by":"crossref","unstructured":"Carrieri, P., Cailleton, V., Le Moing, V. et al. (2001). The dynamic of adherence to highly active antiretroviral therapy: results from the French National APROCO cohort. Journal of Acquired Immune Deficiency Syndromes28, 232\u20139.","DOI":"10.1097\/00042560-200111010-00005"},{"key":"key\n\t\t\t\t20171012173625_R4","doi-asserted-by":"crossref","unstructured":"Moorman, A., Holmberg, S., Marlowe, S. et al. (1999). Changing conditions and treatments in a dynamic cohort of ambulatory HIV patients: the HIV outpatient study (HOPS). Annals of Epidemiology9, 349\u201357.","DOI":"10.1016\/S1047-2797(99)00005-8"},{"key":"key\n\t\t\t\t20171012173625_R5","doi-asserted-by":"crossref","unstructured":"Bastard, J., Caron, M., Vidal, H. et al. (2002). Association between altered expression of adipogenic factor SREBP1 in lipoatrophic adipose tissue from HIV-1-infected patients and abnormal adipocyte differentiation and insulin resistance. Lancet359, 1026\u201331.","DOI":"10.1016\/S0140-6736(02)08094-7"},{"key":"key\n\t\t\t\t20171012173625_R6","doi-asserted-by":"crossref","unstructured":"Martinez, E., Conget, I., Lozano, L. et al. (1999). Reversion of metabolic abnormalities after switching from HIV-1 protease inhibitors to nevirapine. AIDS13, 805\u201310.","DOI":"10.1097\/00002030-199905070-00009"},{"key":"key\n\t\t\t\t20171012173625_R7","doi-asserted-by":"crossref","unstructured":"Carr, A., Hudson, J., Chuah, J. et al. (2001). HIV protease inhibitor substitution in patients with lipodystrophy: a randomised, controlled, open-label, multicentre study. AIDS15, 1811\u201322.","DOI":"10.1097\/00002030-200109280-00010"},{"key":"key\n\t\t\t\t20171012173625_R8","doi-asserted-by":"crossref","unstructured":"Martin, A., Smith, D., Carr, A. et al. (2004). Progression of lipodystrophy (LD) with continued thymidine analogue usage: long-term follow-up from a randomised clinical trial (The PIILR Study). HIV Clinical Trials5, 192\u2013200.","DOI":"10.1310\/0GU7-6X27-MMHE-5ALE"},{"key":"key\n\t\t\t\t20171012173625_R9","doi-asserted-by":"crossref","unstructured":"Ruiz, L., Negredo, E., Domingo, P. et al. (2001). Antiretroviral treatment simplification with nevirapine in protease inhibitor-experienced patients with HIV-associated lipodystrophy: 1-year prospective follow-up of a multicentre, randomised, controlled study. Journal of Acquired Immune Deficiency Syndromes and Human Retrovirology27, 229\u201336.","DOI":"10.1097\/00042560-200107010-00003"},{"key":"key\n\t\t\t\t20171012173625_R10","doi-asserted-by":"crossref","unstructured":"Saint-Marc, T., Partisani, M., Poizot-Martin, I. et al. (1999). A syndrome of peripheral fat wasting (lipodystrophy) in patients receiving long-term nucleoside analogue therapy. AIDS13, 1659\u201367.","DOI":"10.1097\/00002030-199909100-00009"},{"key":"key\n\t\t\t\t20171012173625_R11","doi-asserted-by":"crossref","unstructured":"Mallal, S., John, M., Moore, C. et al. (2000). Contribution of nucleoside analogue reverse transcriptase inhibitors to subcutaneous fat wasting in patients with HIV infection. AIDS14, 1309\u201316.","DOI":"10.1097\/00002030-200007070-00002"},{"key":"key\n\t\t\t\t20171012173625_R12","doi-asserted-by":"crossref","unstructured":"Mallon, P., Miller, J., Cooper, D. et al. (2003). Prospective evaluation of the effects of antiretroviral therapy on body composition in HIV-1-infected men starting therapy. AIDS17, 971\u20139.","DOI":"10.1097\/00002030-200305020-00005"},{"key":"key\n\t\t\t\t20171012173625_R13","doi-asserted-by":"crossref","unstructured":"Lewis, W. & Dalakas, M. (1995). Mitochondrial toxicity of antiviral drugs. Nature Medicine1, 417\u201322.","DOI":"10.1038\/nm0595-417"},{"key":"key\n\t\t\t\t20171012173625_R14","doi-asserted-by":"crossref","unstructured":"Brinkman, K., Smeitink, J., Romijn, J. et al. (1999). Mitochondrial toxicity induced by nucleoside-analogue reverse-transcriptase inhibitors is a key factor in the pathogenesis of antiretroviral-therapy-related lipodystrophy. Lancet354, 1112\u20135.","DOI":"10.1016\/S0140-6736(99)06102-4"},{"key":"key\n\t\t\t\t20171012173625_R15","doi-asserted-by":"crossref","unstructured":"Shikuma, C., Hu, N., Milne, C. et al. (2001). Mitochondrial DNA decrease in subcutaneous adipose tissue of HIV-infected individuals with peripheral lipoatrophy. AIDS15, 1801\u20139.","DOI":"10.1097\/00002030-200109280-00009"},{"key":"key\n\t\t\t\t20171012173625_R16","doi-asserted-by":"crossref","unstructured":"Pace, C., Martin, A., Hammond, E. et al. (2003). Mitochondrial proliferation, DNA depletion and adipocyte differentiation in subcutaneous adipose tissue of HIV-positive HAART recipients. Antiviral Therapy8, 323\u201331.","DOI":"10.1177\/135965350300800409"},{"key":"key\n\t\t\t\t20171012173625_R17","doi-asserted-by":"crossref","unstructured":"Nolan, D., Hammond, E., James, I. et al. (2003) Contribution of nucleoside-analogue reverse transcriptase inhibitor therapy to lipoatrophy from the population to the cellular level. Antiviral Therapy8617\u201326.","DOI":"10.1177\/135965350300800614"},{"key":"key\n\t\t\t\t20171012173625_R18","doi-asserted-by":"crossref","unstructured":"van der Valk, M., Casula, M., Weverlingz, G. et al. (2004). Prevalence of lipoatrophy and mitochondrial DNA content of blood and subcutaneous fat in HIV-1-infected patients randomly allocated to zidovudine- or stavudine-based therapy. Antiviral Therapy9, 385\u201393.","DOI":"10.1177\/135965350400900317"},{"key":"key\n\t\t\t\t20171012173625_R19","doi-asserted-by":"crossref","unstructured":"Carr, A., Workman, C., Smith, D. et al. (2002). Abacavir substitution for nucleoside analogs in patients with HIV lipoatrophy: a randomised trial. Journal of the American Medical Association288, 207\u201315.","DOI":"10.1001\/jama.288.2.207"},{"key":"key\n\t\t\t\t20171012173625_R20","doi-asserted-by":"crossref","unstructured":"Martin, A., Smith, D., Carr, A. et al. (2004). Reversibility of lipoatrophy in HIV-infected patients 2 years after switching from a thymidine analogue to abacavir: the MITOX extension study. AIDS18, 1029\u201336.","DOI":"10.1097\/00002030-200404300-00011"},{"key":"key\n\t\t\t\t20171012173625_R21","doi-asserted-by":"crossref","unstructured":"Smith, D., Carr, A., Law, M. et al. (2002). Thymidine analogue withdrawal for lipoatrophic patients on protease-sparing therapy improves lipoatrophy but compromises antiviral control: the PIILR extension study. AIDS16, 2489\u201391.","DOI":"10.1097\/00002030-200212060-00020"},{"key":"key\n\t\t\t\t20171012173625_R22","doi-asserted-by":"crossref","unstructured":"Moyle, G., Baldwin, C., Langroudi, B. et al. (2003). A 48-week, randomised, open-label comparison of three abacavir-based substitution approaches in the management of dyslipidemia and peripheral lipoatrophy. Journal of Acquired Immune Deficiency Syndromes33, 22\u20138.","DOI":"10.1097\/00126334-200305010-00004"},{"key":"key\n\t\t\t\t20171012173625_R23","doi-asserted-by":"crossref","unstructured":"John, M., McKinnon, E., James, I. et al. (2003). Randomised, controlled, 48-week study of switching stavudine and\/or protease inhibitors to combivir\/abacavir to prevent or reverse lipoatrophy in HIV-infected patients. Journal of Acquired Immune Deficiency Syndromes33, 29\u201333.","DOI":"10.1097\/00126334-200305010-00005"},{"key":"key\n\t\t\t\t20171012173625_R24","unstructured":"Shlay, J.C., Visnegarwala, F., Bartsch, G., et al. (2003) Rates of change in body composition among antiretroviral-naive HIV-infected patients randomized to didanosine\/stavudine versus abacavir\/lamivudine containing regimen in the Flexible Initial Retrovirus Suppressive Therapies (FIRST) study (CPCRA 058). In Programme and Abstracts of the Fifth International Workshop on Adverse Drug Reactions and Lipodystrophy in HIV, Paris, France, 2003. Antiviral Therapy 8, L12, Abstract 13."},{"key":"key\n\t\t\t\t20171012173625_R25","doi-asserted-by":"crossref","unstructured":"Gallant, J. E., Staszewski, S., Pozniak, A. L. et al. (2004). Efficacy and safety of tenofovir DF vs stavudine in combination therapy in antiretroviral-naive patients: a 3-year randomized trial. Journal of the American Medical Association292, 191\u2013201.","DOI":"10.1001\/jama.292.2.191"},{"key":"key\n\t\t\t\t20171012173625_R26","doi-asserted-by":"crossref","unstructured":"Chaput, E., Saladin, R., Silvestre, M. et al. (2000). Fenofibrate and rosiglitazone lower serum triglycerides with opposing effects on body weight. Biochemical and Biophysical Research Communications271, 445\u201350.","DOI":"10.1006\/bbrc.2000.2647"},{"key":"key\n\t\t\t\t20171012173625_R27","doi-asserted-by":"crossref","unstructured":"Arioglu, E., Duncan-Morin, J., Sebring, N. et al. (2000). Efficacy and safety of troglitazone in the treatment of lipodystrophy syndromes. Annals of Internal Medicine133, 263\u201374.","DOI":"10.7326\/0003-4819-133-4-200008150-00009"},{"key":"key\n\t\t\t\t20171012173625_R28","doi-asserted-by":"crossref","unstructured":"Hadigan, C., Yawetz, S., Thomas, A. et al. (2004). Metabolic effects of rosiglitazone in HIV lipodystrophy: a randomised, controlled trial. Annals of Internal Medicine140, 786\u201394.","DOI":"10.7326\/0003-4819-140-10-200405180-00008"},{"key":"key\n\t\t\t\t20171012173625_R29","doi-asserted-by":"crossref","unstructured":"Carr, A., Workman, C., Carey, D. et al. (2004). No effect of rosiglitazone for treatment of HIV-1 lipoatrophy: randomised, double-blind, placebo-controlled trial. Lancet363, 429\u201338.","DOI":"10.1016\/S0140-6736(04)15489-5"},{"key":"key\n\t\t\t\t20171012173625_R30","doi-asserted-by":"crossref","unstructured":"Levan, P., Nguyen, T. H., Lallemand, F. et al. (2002). Correction of facial lipoatrophy in HIV-infected patients on highly active antiretroviral therapy by injection of autologous fatty tissue. AIDS16, 1985\u20137.","DOI":"10.1097\/00002030-200209270-00026"},{"key":"key\n\t\t\t\t20171012173625_R31","unstructured":"Guaraldi, G., Orlando, G., De Fazio, D., et al. (2004) Long-term follow-up of graft hypertrophy after autologous fat transfer for HIV-related face lipoatrophy (hamster syndrome 1 year later). In Programme and Abstracts of the Sixth International Workshop on Adverse Drug Reactions and Lipodystrophy in HIV, Washington, DC, 2004. Antiviral Therapy 9, L52, Abstract 90."},{"key":"key\n\t\t\t\t20171012173625_R32","doi-asserted-by":"crossref","unstructured":"Valantin, M. A., Aubron-Olivier, C., Ghosn, J. et al. (2003). Polylactic acid implants (New-Fill) to correct facial lipoatrophy in HIV-infected patients: results of the open-label study VEGA. AIDS17, 2471\u20137.","DOI":"10.1097\/00002030-200311210-00009"},{"key":"key\n\t\t\t\t20171012173625_R33","doi-asserted-by":"crossref","unstructured":"Hadigan, C., Corcoran, C., Basgoz, N. et al. (2000). Metformin in the treatment of HIV lipodystrophy syndrome: a randomised controlled trial. Journal of the American Medical Association284, 472\u20137.","DOI":"10.1001\/jama.284.4.472"},{"key":"key\n\t\t\t\t20171012173625_R34","doi-asserted-by":"crossref","unstructured":"Miller, J., Brown, D., Amin, J. et al. (2002). A randomised, double-blind study of gemfibrozil for the treatment of protease inhibitor-associated hypertriglyceridaemia. AIDS16, 2195\u2013200.","DOI":"10.1097\/00002030-200211080-00012"},{"key":"key\n\t\t\t\t20171012173625_R35","doi-asserted-by":"crossref","unstructured":"Moyle, G., Lloyd, M., Reynolds, B. et al. (2001). Dietary advice with or without pravastatin for the management of hypercholesterolaemia associated with protease inhibitor therapy. AIDS15, 1503\u20138.","DOI":"10.1097\/00002030-200108170-00007"},{"key":"key\n\t\t\t\t20171012173625_R36","doi-asserted-by":"crossref","unstructured":"Wanke, C., Gerrior, J., Kantaros, J. et al. (1999). Recombinant human growth hormone improves the fat redistribution syndrome (lipodystrophy) in patients with HIV. AIDS13, 2099\u2013103.","DOI":"10.1097\/00002030-199910220-00013"},{"key":"key\n\t\t\t\t20171012173625_R37","doi-asserted-by":"crossref","unstructured":"Koutkia, P., Canavan, B., Breu, J. et al. (2004). Growth hormone-releasing hormone in HIV-infected men with lipodystrophy: a randomized controlled trial. Journal of the American Medical Association292, 210\u20138.","DOI":"10.1001\/jama.292.2.210"}],"container-title":["Journal of Antimicrobial Chemotherapy"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/academic.oup.com\/jac\/article-pdf\/55\/5\/612\/2030374\/dki062.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,1,24]],"date-time":"2024-01-24T01:01:51Z","timestamp":1706058111000},"score":1,"resource":{"primary":{"URL":"http:\/\/academic.oup.com\/jac\/article\/55\/5\/612\/691132\/Therapeutic-approaches-to-combating-lipoatrophy-do"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2005,5,1]]},"references-count":37,"journal-issue":{"issue":"5","published-online":{"date-parts":[[2005,5]]},"published-print":{"date-parts":[[2005,5,1]]}},"URL":"https:\/\/doi.org\/10.1093\/jac\/dki062","relation":{},"ISSN":["1460-2091","0305-7453"],"issn-type":[{"value":"1460-2091","type":"electronic"},{"value":"0305-7453","type":"print"}],"subject":[],"published-other":{"date-parts":[[2005,5]]},"published":{"date-parts":[[2005,5,1]]}}}